Knee replacement
A 2023 peer-reviewed RCT in arthroplasty patients — the evidence extending to one of the highest-volume orthopedic procedures.
TL;DR
A 2023 peer-reviewed orthopedic RCT found approximately 50% reduction in post-operative pain in tPEMF-treated patients following total knee arthroplasty. Knee replacement is one of the highest-volume surgical procedures in the US, and post-operative pain management drives both the discharge timeline and the risk of chronic opioid use.
A 2023 randomized controlled trial in patients undergoing total knee arthroplasty (TKA) found approximately 50% reduction in post-operative pain in the tPEMF-treated group versus control. Total knee replacement is among the most-performed elective surgical procedures in the US, with over 700,000 procedures annually — making even a modest per-patient improvement in pain management and opioid use consequential at the population level.
TKA is a high-pain procedure performed on an older patient population that already carries comorbidities limiting pharmacologic options. NSAIDs are constrained by cardiovascular and renal risk. Opioids carry particular risks in this age group (falls, delirium, constipation). Physical therapy — critical to a good TKA outcome — is compromised by uncontrolled pain. A non-pharmacologic adjunct that demonstrably reduces pain has a clear role in the TKA recovery protocol.
The 2023 orthopedic RCT enrolled TKA patients across a surgical center and randomized them to active tPEMF or control. Pain was measured on a validated scale at standardized post-operative timepoints. The device was applied over the dressing beginning in the recovery room, demonstrating compatibility with standard wound-care protocols. The 50% pain reduction is the primary outcome; the finding in a 2023 publication extends the evidentiary record from the 2008–2010 plastic surgery trials into the contemporary orthopedic setting.
For a knee-replacement patient, 50% less pain in the first post-operative days means a more tolerable early physical therapy experience — the phase where range-of-motion gains are most critical and most dependent on the patient's willingness to push through discomfort. It means less opioid use in the period when opioid-induced constipation and delirium are most likely to prolong the hospital stay. For a patient whose surgeon has told them to expect significant pain, the evidence of a 50% reduction is the most credible possible motivation to request the device before surgery.
TKA pain management has advanced substantially with multimodal protocols, nerve blocks (femoral, adductor canal), and periarticular injections (bupivacaine, ketorolac, epinephrine). These interventions meaningfully reduce early pain but are performed in the operating room and do not extend to home recovery. tPEMF works through the dressing, at home, on the patient's own schedule — a different phase of the recovery arc than what nerve blocks address. The two approaches are complementary: nerve blocks cover the first 12–24 hours in-hospital; tPEMF covers the 7–10 days of peak home-recovery inflammatory pain.
Sources & references
Related